GSK PLC (LSE:GSK)
£ 18.1 0.105 (0.58%) Market Cap: 73.81 Bil Enterprise Value: 87.49 Bil PE Ratio: 17.87 PB Ratio: 5.33 GF Score: 77/100

Iteos Therapeutics Inc to Discuss Collaboration with GlaxoSmithKline PLC for EOS-448 Call Transcript

Jun 14, 2021 / 12:30PM GMT
Release Date Price: £14.18 (+0.29%)
Operator

Good morning, and welcome to the iTeos Therapeutics Business Update Conference Call. (Operator Instructions) Please be advised this call is being recorded at the company's request.

At this time, I'd like to turn it over to Ryan Baker, Head of Investor Relations at iTeos.

Ryan Baker
iTeos Therapeutics, Inc. - Head of IR

Thank you for joining us today. Joining me from iTeos are Michel Detheux, President and CEO; Matthew Gall, Chief Financial Officer; Matt Call, Chief Operating Officer; and Dr. Jo Lager, Chief Medical Officer. This morning, iTeos issued a news release announcing that it has entered into a partnership with GlaxoSmithKline to co-develop and co-commercialize iTeos' anti-TIGIT antibody, EOS-448, as a potential treatment for people with cancer.

Before I turn the call over to Michel to discuss the details of the partnership, I would like to note that the team will be making forward-looking statements in the prepared remarks and during the Q&A session. Please take a moment to review Slide #2 on the webcast, which contains our

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot